{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Table 1', 'Schedule of Assessments for Arms A and B', 'Long Term', 'End of', 'Post treatment', 'Treatment', 'Survival', 'Visit', 'Screening/Baseline\u00b9', 'Every Cycle', 'Treatment21', 'Follow-up18', 'Follow-Up', 'Follow-up', 'Follow-up', 'Day 8', 'Day 15', 'Date of last', 'Day -28', 'Day -7', 'Every', 'Date of Last', 'Every 3', 'Arm A', 'Arm A', 'Dose +30', 'to -1', 'Every 56 days', 'Every 3', 'Day 1', 'to -1', 'Dose', 'Base Date', '56 Days', 'months', 'months', '(only)', '(only)', 'days', '3', 'Visit Window', 'NA', 'NA', '3 day', 'days', '3 days', '7 days', '+ 7 days', '+ 7 days', '7 days', '7 days', '7 days', 'Informed Consent', 'X', 'Medical and Disease History', 'X', 'Confirmation of Eligibility', 'X', 'Tumor Tissue Sample\u00b2', 'X', 'Brain Scan\u00b3', 'X', 'X', 'X', 'Bone Scan4', 'X', 'X', 'X', 'PGx blood sample (optional)', 'X', 'Serum/Urine Pregnancy Test5', 'X', 'X', 'X', 'X', 'X5', 'X5', 'X5', 'Physical Examination', '6', 'X', 'X', 'X', 'Weight', 'X', 'X', 'X6', 'X6', 'X', 'Vital Signs', 'X', 'X', 'X6', 'X6', 'X', 'X', 'Biochemistry7', 'X', 'X', 'X7', 'X7', 'X', 'X', 'Hemoglobin A1C8', 'X', 'X', 'Hematology9', 'X', 'X', 'X9', 'X9', 'X', 'X', 'ECOG PS', 'X', 'X', 'X', 'X', '12-lead ECG10', 'X', 'X', 'Ophthalmology Assessment11', 'X', 'X', 'Randomization12', 'X', 'Arm A: EV Administration - 28', 'X', 'X', 'X', 'Day Cycle13', 'Arm B: Docetaxel/Paclitaxel/', 'Vinflunine Administration - 21', 'X', 'Day Cycle14', 'Table continued on next page', '14 Sep 2020', 'Astellas', 'Page 32 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Long Term', 'Screening/Baseline', 'End of', 'Post treatment', 'Treatment', 'Survival', 'Visit', '1', 'Every Cycle', 'Treatment', 'Follow-up18', 'Follow-Up', 'Follow-up', 'Follow-up', 'Day 8', 'Day 15', 'Date of last', 'Day -28', 'Day -7', 'Every', 'Date of Last', 'Day 1', 'Arm A', 'Arm A', 'Dose +30', 'Dose', 'Every 56 days', 'Every 3 months', 'Every 3', 'to -1', 'to -1', 'Base Date', '56 Days', 'months', '(only)', '(only)', 'days', '3', '3', 'Visit Window', 'NA', 'NA', '3 day', 'days', 'days', '7 days', '+ 7 days', '+ 7 days', '7 days', '7 days', '7 days', 'Image Assessment1:', 'X', 'X15', 'X 19', 'Subsequent Therapy Assessment20', 'X', 'X', 'X', 'X', 'Concomitant Medication', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'AE', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'QOL16', 'X', 'X', 'X', 'X', 'HRU22', 'X22', 'X', 'X', 'Overall Survival17', 'X', 'X', 'X', 'X', 'AE: adverse event; ALT: alanine transaminase; AST: aspartate transaminase; CR: complete response; CT: computed tomography; ECG: electrocardiogram; ECOG PS: Eastern', 'Cooperative Oncology Group Performance Status; EORTC-QLQ-C30: European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire; EOT: end of', 'treatment; EQ-5D-5L: EuroQOI 5-Dimension 5-Level Questionnaire; EV: enfortumab vedotin; HRU: health resource utilization; MRI: magnetic resonance imaging; NA: Not', 'Applicable; PD: progressive disease; PFS1: progression free survival on study therapy; PFS2: progression free survival on subsequent therapy; PGx: Pharmacogenetic analyses; PR:', 'partial response; QOL: quality of life; RECIST: Response Evaluation Criteria in Solid Tumors', '1. Screening period is 28 days. Subjects may have screening assessments repeated once. If more than 1 assessment is taken during the screening, the assessment closest to', 'enrollment date should be used for eligibility.', '2. Archival tumor tissue (from primary or metastatic site) for biomarker studies should be available for submission to the Sponsor prior to study treatment. If an archival tumor', 'tissue sample is not available, a fresh tissue sample should be provided. A tissue block or a minimum of 10 and up to 15 freshly sectioned, unstained charged slides should be', 'provided.', '3. Only if clinically indicated at baseline. Repeat as clinically indicated or per standard of care throughout the study.', '4. All subjects will have a baseline bone scan (scintigraphy) performed at screening. Subjects with positive bone scans at baseline will have a bone scan performed every 56 days', '( 7 days) throughout the study or more frequently if clinically indicated. Subjects should have a follow-up bone scan performed if clinically indicated regardless of baseline', 'status.', '5. For all female subjects of child bearing potential only, a urine or serum pregnancy test will be performed at baseline. A urine or serum pregnancy test will then be repeated on', 'day 1 of each cycle prior to EV or chemotherapy administration, at EOT and Follow-up visits. After EOT, a monthly ( 7 days) pregnancy test will be maintained until', '6 months after the last dose of study treatment.', 'Footnotes continued on next page', '14 Sep 2020', 'Astellas', 'Page 33 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}